Andra AP fonden Sells 8,600 Shares of Illumina, Inc. (NASDAQ:ILMN)

Andra AP fonden lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 20.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 34,100 shares of the life sciences company’s stock after selling 8,600 shares during the period. Andra AP fonden’s holdings in Illumina were worth $4,557,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. WCM Investment Management LLC raised its holdings in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after acquiring an additional 867,673 shares during the period. Bank of New York Mellon Corp increased its holdings in Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock worth $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after purchasing an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after buying an additional 625,245 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 2.3 %

Shares of Illumina stock opened at $86.62 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business has a fifty day simple moving average of $118.38 and a two-hundred day simple moving average of $131.49. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The company has a market capitalization of $13.72 billion, a price-to-earnings ratio of -11.28, a P/E/G ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Royal Bank of Canada dropped their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $149.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.